IL125950D0 - Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy - Google Patents

Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy

Info

Publication number
IL125950D0
IL125950D0 IL12595098A IL12595098A IL125950D0 IL 125950 D0 IL125950 D0 IL 125950D0 IL 12595098 A IL12595098 A IL 12595098A IL 12595098 A IL12595098 A IL 12595098A IL 125950 D0 IL125950 D0 IL 125950D0
Authority
IL
Israel
Prior art keywords
administering
methods
receptor antagonists
dopamine agonist
ampa receptor
Prior art date
Application number
IL12595098A
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US5809897P priority Critical
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL125950D0 publication Critical patent/IL125950D0/en

Links

IL12595098A 1997-09-05 1998-08-27 Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy IL125950D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US5809897P true 1997-09-05 1997-09-05

Publications (1)

Publication Number Publication Date
IL125950D0 true IL125950D0 (en) 1999-04-11

Family

ID=22014669

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12595098A IL125950D0 (en) 1997-09-05 1998-08-27 Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy

Country Status (10)

Country Link
US (1) US6136812A (en)
EP (1) EP0900568A3 (en)
JP (2) JPH11158072A (en)
KR (1) KR100440659B1 (en)
AU (1) AU736254B2 (en)
CA (1) CA2246839C (en)
HU (1) HU9802021A3 (en)
IL (1) IL125950D0 (en)
NZ (1) NZ331741A (en)
ZA (1) ZA9808139B (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627755B1 (en) * 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US7671200B2 (en) * 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
JP4642309B2 (en) * 2000-04-25 2011-03-02 イコス・コーポレイションIcos Corporation Human phosphatidyl - inositol 3-kinase delta inhibitor
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
GB0017952D0 (en) * 2000-07-22 2000-09-13 Univ Manchester Treatment of dyskinesia
DE60215203T2 (en) * 2001-09-12 2007-10-18 Merck Patent Gmbh USE OF AMINOMETHYL chromans FOR TREATING side effects of neuroleptics
AU2002366103A1 (en) * 2001-11-19 2003-06-10 Iconix Pharmaceuticals, Inc. Modulators of rho c activity
WO2003043995A1 (en) 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
AT372341T (en) * 2001-12-06 2007-09-15 Merck & Co Inc Inhibitors of mitotic kinesin
WO2003070701A2 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Syntheses of quinazolinones
EP1553931A4 (en) * 2002-05-09 2006-08-30 Cytokinetics Inc Compounds, compositions, and methods
CA2485148A1 (en) 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
AU2003265242A1 (en) * 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003236527A1 (en) * 2002-06-14 2003-12-31 Cytokinetics, Inc. Compounds, compositions, and methods
EP1537089A4 (en) 2002-07-23 2008-04-16 Cytokinetics Inc Compounds compositions and methods
AT358488T (en) * 2002-09-13 2007-04-15 Motac Neuroscience Ltd 2,3-benzodiazepines with treatment of dyskinesia
JP2006501306A (en) 2002-09-30 2006-01-12 サイトキネティクス・インコーポレーテッドCytokinetics Incorporated Compounds, compositions and methods
US7687625B2 (en) * 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007510652A (en) * 2003-11-03 2007-04-26 サイトキネティクス・インコーポレーテッドCytokinetics Incorporated Pyrimidin-4-one compounds, compositions, and methods
US7439254B2 (en) * 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
EP1761540B1 (en) 2004-05-13 2016-09-28 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
BRPI0607913A2 (en) * 2005-04-08 2010-03-23 Eisai R&D Man Co Ltd therapeutic agent for dyskinesia
CA2607929A1 (en) * 2005-05-11 2006-11-16 Merck Sharp & Dohme Limited 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1)
ES2376351T5 (en) 2005-09-14 2014-07-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase for treating diabetes
CN102675221A (en) 2005-09-16 2012-09-19 武田药品工业株式会社 Intermediate in method for preparing pyrimidinedione derivative
TWI409070B (en) * 2005-11-04 2013-09-21 Hydra Biosciences Inc Compounds for modulating trpv3 function
CA2660951A1 (en) * 2006-08-23 2008-02-28 Neurogen Corporation Haloalkyl-substituted pyrimidinone derivatives
WO2008024438A2 (en) 2006-08-23 2008-02-28 Neurogen Corporation 2-phenoxy pyrimidinone analogues
MX2009003673A (en) 2006-10-04 2009-04-22 Pfizer Prod Inc Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists.
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
WO2008140750A1 (en) * 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
KR20160091440A (en) 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US8822462B2 (en) * 2009-01-28 2014-09-02 Emory University Subunit selective NMDA receptor potentiators for the treatment of neurological conditions
EA019499B1 (en) 2009-03-24 2014-04-30 ГИЛИЭД КАЛИСТОГА ЭлЭлСи Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
WO2010123931A1 (en) 2009-04-20 2010-10-28 Calistoga Pharmaceuticals Inc. Methods of treatment for solid tumors
EP2456443A1 (en) 2009-07-21 2012-05-30 Gilead Calistoga LLC Treatment of liver disorders with pi3k inhibitors
CA2864305A1 (en) 2012-03-05 2013-09-12 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
AU2014364414A1 (en) 2013-12-20 2016-06-30 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
AU2014364410B2 (en) 2013-12-20 2017-11-16 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
EP3317277A4 (en) 2015-07-01 2018-12-19 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4183931A (en) * 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
US5395827A (en) * 1986-04-09 1995-03-07 Guilford Pharmaceuticals Inc. ω-[2-(phosphonoalkyl)phenyl]-2-aminoalkanoic acids as antagonists of excitatory amino acid receptors
US5268378A (en) * 1990-05-31 1993-12-07 Merck Sharp & Dohme, Limited Dioxo-tetrahydroquinoline derivatives
GB9022785D0 (en) * 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
GB9026389D0 (en) * 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
US5639751A (en) * 1990-12-21 1997-06-17 Cyogyszerkutato Intezet Kft N-acyl-2,3-benzodiazepine derivatives for treating acute and chronic neurodegenerative disorders
US5521174A (en) * 1990-12-21 1996-05-28 Gyogyszerkutato Intezet Kv. N-acyl-2,3-benzodiazepine derivatives and a method of treating spasms of the skeletal musculature therewith
US5519019A (en) * 1990-12-21 1996-05-21 Gyogyszerkutato Intezet N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions containing them and process for preparing same
WO1992013535A1 (en) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
AT162075T (en) * 1991-09-09 1998-01-15 Warner Lambert Co A pharmaceutical combination product containing a uricosurisches medium and an excitatory amino acid antagonists
DK162491D0 (en) * 1991-09-20 1991-09-20 Novo Nordisk As Heterocyclic compounds, their preparation and pharmaceutical compositions containing the compounds
PT101004B (en) * 1991-10-26 1999-10-29 Schering Ag Quinoxaline derivatives, process for their preparation and pharmaceutical compositions containing them
GB9125515D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
GB9125485D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
GB9200781D0 (en) * 1992-01-15 1992-03-11 Merck Sharp & Dohme Therapeutic agents
GB9206266D0 (en) * 1992-03-23 1992-05-06 Merck Sharp & Dohme Therapeutic agents
GB9210393D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
US5631373A (en) * 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
DE69334237D1 (en) * 1992-06-22 2008-09-25 State Of Oregon Through Oregon Glycine receptor antagonists and their use
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) * 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5364876A (en) * 1992-12-02 1994-11-15 Guilford Pharmaceuticals Inc. Omega-[2-(alkyl)phenyl]-2-aminoalkanoic acids as antagonists of excitatory amino acid receptors
US5342946A (en) * 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
DK31093D0 (en) * 1993-03-19 1993-03-19 Novo Nordisk As
AT148120T (en) * 1993-05-06 1997-02-15 Novo Nordisk As (1,2,4-triazolo (4,3-a> quinoxaline their preparation and use
EP0743945B1 (en) * 1994-02-11 2002-03-06 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5580877A (en) * 1994-04-25 1996-12-03 Merck Sharp & Dohme Ltd. Pyrazolo-quinoline derivatives for treating cerebral ischemia
US5446051A (en) * 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
WO1996008493A1 (en) * 1994-09-16 1996-03-21 Novo Nordisk A/S [1,2,4]TRIAZOLO[4,3-a]QUINOXALINONE DERIVATIVES, THEIR PREPARATION AND USE
US5654303A (en) * 1995-06-07 1997-08-05 Warner-Lambert Company Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US5614508A (en) * 1995-06-07 1997-03-25 Warner-Lambert Company Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists
CZ295565B6 (en) * 1996-05-15 2005-08-17 Pfizer Inc. 2,3-Disubstituted-4-(3H)-quinazolinones, their use and pharmaceutical compositions based thereon

Also Published As

Publication number Publication date
JPH11158072A (en) 1999-06-15
EP0900568A3 (en) 2001-05-02
US6136812A (en) 2000-10-24
JP2001316267A (en) 2001-11-13
HU9802021A2 (en) 1999-05-28
NZ331741A (en) 2000-08-25
HU9802021D0 (en) 1998-10-28
AU8312098A (en) 1999-03-18
AU736254B2 (en) 2001-07-26
ZA9808139B (en) 2000-03-22
KR19990029570A (en) 1999-04-26
HU9802021A3 (en) 2001-05-28
CA2246839A1 (en) 1999-03-05
KR100440659B1 (en) 2004-12-17
CA2246839C (en) 2002-11-12
EP0900568A2 (en) 1999-03-10

Similar Documents

Publication Publication Date Title
AU777970C (en) Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
TW450808B (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
AU743229C (en) Transdermal therapeutic system containing pergolide
GB2316004B (en) Novel formulations for transdermal delivery of pergolide
PL317381A1 (en) Derivatives of quinoline as antagonists of tachykynin receptors nk3
HK1016087A1 (en) Treatment of prostate cancer with lhrh antagonists.
AU7740500A (en) A chamber for applying therapeutic substances to an implantable device
IL142132D0 (en) Methods and compositions for treating receptor mediated diseases
AU7406596A (en) Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation and their use
ZA9800979B (en) Method of treating dry eye disease with purinergic receptor agonists
PL343589A1 (en) Device for the transdermal delivery of diclofenac
EP1017713A4 (en) CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS
WO2003015693A3 (en) Screening and therapeutic methods for promoting wakefulness and sleep
EE200100403A (en) Indole derivatives and their use as antagonists of the MCP-1
HK1002280A1 (en) Benzimidazole derivatives, their preparation and their therapeutic use
AU9500801A (en) Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
GB9713703D0 (en) Preparation of opiates
IL148157A (en) Heteropolycyclic compounds, pharmaceutical compositions comprising them and their use in medicaments for treating diseases associated with metabotropic glutamate receptors
HU0104129A3 (en) Use of 2-phenylbenzimidazoles and 2-phenylindoles for producing pharmaceutical compositions having parp enzym effect and new 2-phenylbenzimidazol derivatives
IL146082A (en) Use of an 1l-13 antagonist for the manufacture of a medicament for treating tissue fibrosis
IL143303D0 (en) Substituted benzimidazoles and their use as parp inhibitors
HK1014881A1 (en) Epidural administration of therapeutic compounds with sustained rate of release
AU7109000A (en) Dibenzopyrans as glucocorticoid receptor antagonists for treatment of diabetes
AU1293101A (en) Ep4 receptor selective agonists in the treatment of osteoporosis
IL147089D0 (en) Methods of preparing lipid-encapsulated therapeutic agents